AUTL News and Press, Autolus Therapeutics plc From 12/08/22

Autolus Therapeutics ( NASDAQ: AUTL ) on Thursday said an interim analysis of a phase 2 study of its investigational CAR-T cell therapy obe-cel for the treatment of a type of blood cancer found that the trial had met its main goal. According to the interim analysis, obe-cel showed an ...

Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL) Encouraging safety data observed, with 3% ≥Grade 3 Cytokine Release Syndrome (CRS) and 8% ≥Grade 3 Immune eff...

LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the handover of the first of three clean rooms forming the basis of its new commercial manufac...

Summary Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia expected in Q4 of 2022. With positive results, a Biologics Licensing Application of obe-cel for the treatment of patients...

Autolus Therapeutics plc (AUTL) Q3 2022 Earnings Conference Call November 03, 2022 08:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference C...

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2022 Q3 earnings call. For further details see: Autolus Therapeutics plc 2022 Q3 - Results - Earnings Call Presentation

obe-cel: poster presentation in B-ALL and B-NHL patients AUTO1/22: poster presentation in pediatric ALL patients AUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a cli...

Autolus Therapeutics press release ( NASDAQ: AUTL ): Q3 GAAP EPS of -$0.47 in-line. Revenue of $2.37M (+887.5% Y/Y) beats by $2.23M . Net loss attributable to ordinary shareholders was $42.8 million for the three months ended September 30. For further details...

Pivotal FELIX Phase 2 clinical trial of obe-cel in relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL) on track for Q4 2022 update Commercial manufacturing site build on schedule for handover of first clean rooms to Autolus in Q4 2022 Post-period end announc...

LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2022 financial results and operational highlights...